News

TOMI Environmental Solutions Secures $1.2 Million Contract with Enviro-Mist Inc. Driving SteraMist Growth in the Pharmaceutical Market

FREDERICK, Md., July 24, 2024 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global company specializing in…

1 year ago

ICU Medical Announces Time of Second Quarter 2024 Earnings Conference Call

SAN CLEMENTE, Calif., July 24, 2024 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq: ICUI), a leader in the development, manufacture…

1 year ago

MangoRx Initiates Efficacy Studies on its Patented Respiratory Illness Prevention Technology

Dallas, Texas, July 24, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a leader in men’s…

1 year ago

Catalyst Pharmaceuticals Enters Into an Exclusive License, Supply and Commercialization Agreement with Kye Pharmaceuticals for AGAMREE® in Canada

CORAL GABLES, Fla., July 24, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company…

1 year ago

R1 RCM Special Committee Provides Update on Evaluation of Strategic Alternatives

Sets Final Bid Deadline of July 31, 2024MURRAY, Utah, July 24, 2024 (GLOBE NEWSWIRE) -- The Special Committee of the…

1 year ago

Intra-Cellular Therapies to Host Second Quarter 2024 Financial Results Conference Call and Webcast

NEW YORK, July 24, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and…

1 year ago

ImPact Biotech Receives a €13.5M Investment Commitment from the European Innovation Council’s Accelerator Program

TEL AVIV, Israel, July 24, 2024 (GLOBE NEWSWIRE) -- ImPact Biotech, a clinical-stage biotechnology company focused on developing Padeliporfin vascular…

1 year ago

Fulcrum Therapeutics to Host Second Quarter 2024 Financial Results Conference Call and Webcast on Wednesday, July 31, 2024, at 8:00 a.m. ET

CAMBRIDGE, Mass., July 24, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused…

1 year ago

Madrigal Pharmaceuticals to Release Second-Quarter 2024 Financial Results and Host Webcast on August 7, 2024

CONSHOHOCKEN, Pa., July 24, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that it will release its…

1 year ago

Annovis Bio Secures U.S. Patent for Treatment of Acute Traumatic Brain Injury with Buntanetap

MALVERN, Pa., July 24, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”),…

1 year ago